Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 5;28(10):1591–1605. doi: 10.1177/13524585221083194

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2022

This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 8. — Mean cumulative percentage change from baseline during the study in total brain, thalamic, and cGM volume (between-group comparison—overall population).

Total brain volume: placebo switch to siponimod (N = 457); siponimod (N = 929). Thalamic volume: placebo switch to siponimod (N = 451); siponimod (N = 920). cGM volume: placebo switch to siponimod (N = 448); siponimod (N = 920). MMRM model: percentage change from baseline adjusted for visit, treatment, age, number of Gd+ T1 lesions at baseline, T2 lesion volume (mm³) at baseline, superimposed relapses at baseline, visit by treatment interaction (and baseline normalized brain tissue volume, where applicable).

cGM: cortical gray matter; CP: core part; EP: extension part; Gd+: gadolinium-enhancing; M: month; MMRM: mixed model repeated measures; ns: not significant.